TABLE 2.

Summary of the number of studies (number of participants, risk difference) and the range in risk difference in adverse events in randomized, controlled trials. ^a

Adverse events	Zoledronate vs. placebo	Risedronate vs. placebo	Alendronate vs. placebo	Ibandronate vs. placebo
Gastrointestinal adverse events	0 studies	1 (170, −7.2%)	1 (123, 8.1%)	1 (160, 6.2%)
Death	1 (2000, −1.4%)	0 studies	0 studies	0 studies
Hypercalcemia	1 (50, 0%)	0 studies	2 (169.0% to 1.6%)	0 studies
Hypercalciuria	0 studies	0 studies	1 (123, 4.0%)	0 studies
Cancer	1 (2000, −3.7%)	0 studies	1 (123, 0.8%)	0 studies
Infection	1 (383, −4.4%)	0 studies	1 (123,−0.8%)	0 studies
Composite of vascular events	1 (2000, −1.6%)	0 studies	0 studies	0 studies
Atrial fibrillation	1 (2000, −0.1%)	0 studies	0 studies	0 studies
Musculoskeletal pain	1 (383, 15.7%)	0 studies	0 studies	1 (160, 4.1%)
Nausea	1 (383, 3.6%)	0 studies	0 studies	1 (160, 2.8%)
Arthralgia	1 (383, −0.5%)	0 studies	0 studies	1 (160, 5.9%)
Myocardial infarction	1 (2000, −1.5%)	0 studies	0 studies	0 studies
Osteonecrosis of the jaw	1 (41, 0%)	1 (133, 0%)	0 studies	0 studies

^aThe risk difference was calculated by subtracting the percentage of participants experiencing an adverse event in the placebo or control group from the percentage experiencing an adverse event in the treatment group.